BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 1,091 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00. Following the completion of the transaction, the insider now owns 58,816 shares of the company's stock, valued at $1,470,400. This trade represents a 1.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Sarah Aebersold also recently made the following trade(s):
- On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.
BioLife Solutions Trading Down 4.6 %
NASDAQ BLFS opened at $25.06 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock's 50-day simple moving average is $26.64 and its two-hundred day simple moving average is $25.51. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period last year, the firm posted ($0.21) EPS. Research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Benchmark restated a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. Finally, KeyCorp lifted their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus price target of $29.86.
View Our Latest Analysis on BioLife Solutions
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC purchased a new stake in shares of BioLife Solutions in the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions in the third quarter worth $28,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions in the fourth quarter worth $31,000. Quest Partners LLC purchased a new stake in BioLife Solutions during the third quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. grew its stake in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
